The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Most clinic attenders with chronic hepatitis B (CHB) are serum HBeAg‐negative, and a minority will require suppressive antiviral treatment. Expert guidelines propose schedules for the monitoring of untreated patients, but the recommended frequency of patient review does not reflect recognised demographic determinants of HBeAg‐negative chronic hepatitis. Also, the impact of patient ethnicity on risk...
Hepatitis B virus e antigen (HBeAg) loss and the appearance of antibodies to HBeAg (anti‐HBe) are favourable events in the history of chronic hepatitis B virus (CHB) infection. Most CHB patients have the HBeAg/anti‐HBe profiles +/− or −/+, and little is published on the derivation or fate of the +/+ and −/− profiles. We have used electronically accessible patient data to study the HBeAg and anti‐HBe...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.